The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of RAS mutations on immunologic characteristics of the tumor microenvironment (TME) in patients with microsatellite instability-high (MSI-H) or mismatch-repair–deficient (dMMR) colorectal cancer (CRC).
 
Mohamed E. Salem
Consulting or Advisory Role - Bristol-Myers Squibb; Exelixis; Exelixis; Novartis; Pfizer; QED Therapeutics; Taiho Pharmaceutical
Speakers' Bureau - BMS; Daiichi Sankyo/Astra Zeneca; Merck; Taiho Pharmaceutical
 
Thierry Andre
Honoraria - AMGEN; Bristol-Myers Squibb; GlaxoSmithKline; Merck; Pierre Fabre; Roche/Genentech; SERVIER; Ventana Medical Systems
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca/MedImmune; Bristol-Myers Squibb; GamaMabs Pharma; GlaxoSmithKline; Gritstone Bio; Kaleido Biosciences; MSD Oncology; Pierre Fabre; Seagen; SERVIER; Servier; Tesaro; Transgene
Travel, Accommodations, Expenses - MSD Oncology
(OPTIONAL) Uncompensated Relationships - Adjuvant Colon Cancer End Points (ACCENT) Collaborative Group; ARCAD Foundation; Gercor
 
Sherif Mohamed El-Refai
Employment - Tempus
Stock and Other Ownership Interests - Tempus
 
Scott Kopetz
Stock and Other Ownership Interests - Frontier Medicines; Iylon; Lutris; MolecularMatch
Consulting or Advisory Role - Abbvie; Amal Therapeutics; AstraZeneca/MedImmune; Bayer Health; Bicara Therapeutics; Boehringer Ingelheim; Boston Biomedical; Carina Biotech; Daiichi Sankyo; EMD Serono; EMD Serono; Endeavor BioMedicines; Flame Biosciences; Frontier Medicines; Genentech; Genomic Health; Gilead Sciences; GlaxoSmithKline; HalioDx; Holy Stone Healthcare; Inivata; Ipsen; Iylon; Jacobio; Jazz Pharmaceuticals; Johnson & Johnson/Janssen; Lilly; Lutris; Merck; Mirati Therapeutics; Natera; Novartis; Numab; Pfizer; Pierre Fabre; Redx Pharma; Repare Therapeutics; Replimune; Servier; Taiho Pharmaceutical; Xilis
Research Funding - Amgen; Array BioPharma; Biocartis; Daiichi Sankyo; EMD Serono; Genentech/Roche; Guardant Health; Lilly; MedImmune; Novartis; Sanofi
 
Josep Tabernero
Consulting or Advisory Role - Array BioPharma; AstraZeneca; Avvinity; Bayer; Boehringer Ingelheim; Chugai Pharma; Daiichi Sankyo; F. Hoffmann LaRoche; Genentech; HalioDx; Hutchison MediPharma; Ikena Oncology; Inspirna; IQvia; Lilly; Menarini; Merck Serono; Merus; Mirati Therapeutics; MSD; Neophore; Novartis; Ona Therapeutics; Orion Biotechnology; Peptomyc; Pfizer; Pierre Fabre; Samsung Bioepis; Sanofi; Scandion Oncology; Seagen; Servier; Sotio; Taiho Pharmaceutical; Tessa Therapeutics; TheraMyc
Other Relationship - Imedex; Medscape; MJH Life Sciences; Peerview; Physicans' Education Resource
 
Frank A. Sinicrope
Stock and Other Ownership Interests - illumina
Honoraria - Targeted Oncology
Consulting or Advisory Role - Guardant Health
Research Funding - Ventana Medical Systems (Inst)
Patents, Royalties, Other Intellectual Property - Patent royalty related to immune markers in colon cancer. Patent jointly held between myself and Roche/Ventana Medical Systems. (Inst)
Travel, Accommodations, Expenses - Guardant Health
 
Jeanne Tie
Honoraria - Inivata; SERVIER
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Haystack Oncology; Inivata; MSD Oncology; Pierre Fabre
 
Thomas J. George
Consulting or Advisory Role - Pfizer; Tempus
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Ipsen (Inst); Lilly (Inst); Merck (Inst); OncoC4 (Inst); Seagen (Inst)
 
Eric VanCutsem
No Relationships to Disclose
 
Elizabeth Mauer
Employment - Tempus
Stock and Other Ownership Interests - Tempus
Research Funding - Tempus
Travel, Accommodations, Expenses - Tempus
 
Sara Lonardi
Consulting or Advisory Role - Amgen; AstraZeneca; Bristol-Myers Squibb; Daiichi Sankyo; Incyte; Lilly; Merck Serono; MSD; SERVIER
Speakers' Bureau - Amgen; Bristol-Myers Squibb; GlaxoSmithKline; Lilly; Merck Serono; Pierre Fabre; Roche; Servier
Research Funding - Amgen; AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Merck Serono; Roche (Inst)
 
Michael J. Overman
Consulting or Advisory Role - 3D Medicines; Array BioPharma; Bristol-Myers Squibb; Gritstone Bio; Janssen; Janssen; MedImmune; Merck; Novartis; Pfizer; Pfizer; Promega; Roche/Genentech; Spectrum Pharmaceuticals
Research Funding - Bristol-Myers Squibb; MedImmune; Merck; Roche
 
David Foureau
No Relationships to Disclose